. Author manuscript; available in PMC: 2009 Aug 1.

Published in final edited form as: Cancer Prev Res (Phila). 2008 Aug;1(3):208–214. doi: 10.1158/1940-6207.CAPR-08-0021

Table 3.

Effect of celecoxib and LGD1069 on mammary eicosanoid levels in MMTV/neu mice

Drug Regimen	PGE2, ng/mg protein (P=0.09) ^*	PGD2, ng/mg protein (P=0.15) ^*	LTB4, ng/mg protein (P<0.001) ^*	12-HETE, ng/mg protein (P=0.19) ^*
Vehicle	1.29±0.50	2.86±1.55	0.070±0.029	7.85±2.99
Celecoxib	0.85±0.49 (P=0.46) ^‡	1.45±0.65 (P=0.17) ^‡	0.236±0.082 (P<0.001) ^‡	14.36±7.20 (P=0.11) ^‡
LGD1069	1.50±0.93 (P=0.91) ^‡	2.63±1.82 (P=0.98) ^‡	0.097±0.049 (P=0.78) ^‡	9.04±5.55 (P=0.96) ^‡
Celecoxib and LGD1069	0.62±0.37 (P=0.18) ^‡	1.53±0.57 (P=0.20) ^‡	0.102±0.064 (P=0.69) ^‡	9.79±4.31 (P=0.86) ^‡

P value obtained by one-way ANOVA analysis across the different treatment groups

^‡

P value obtained by comparison with vehicle-treated cohort (using Dunnett’s test and correcting for multiple comparisons)